Gan & Lee Pharmaceuticals Gets China Nod for Breast Cancer Drug Trial

Gan & Lee Pharmaceuticals Secures Honduras Approval for Diabetes Drug; Shares Up 6%

Gan&Lee Pharmaceuticals Secures Honduran Regulatory Approval for Its Insulin Glargine Prefilled Pen

Gan & Lee Pharmaceuticals Gets Honduras Approval for Insulin Jab

Gan & Lee Pharmaceuticals Secures Registration Approval for Insulin Glargine Injection in Honduras

Gan & Lee Pharmaceuticals Seizes a Niche Opportunity in the Insulin Market

Gan & Lee Pharmaceuticals Secures UAE Drug Registration for Insulin Glargine Pre-filled Pen

Gan & Lee Pharmaceuticals - Once-Weekly Insulin Ludefen Shows Favorable Safety Profile With No Severe Hypoglycemia

Gan & Lee Pharmaceuticals - Insulin Ludefen (Gzr4) Meets Primary Endpoint in Phase Iii Trial in China

Gan & Lee Pharmaceuticals Unveils Restricted Stock Incentive Plan for 2026

Gan & Lee Pharmaceuticals Subsidiary Secures ANVISA Sterile Preparation GMP Certification in Brazil

Gan & Lee Pharmaceuticals Receives European Commission Approval for Insulin Lispro Injection

Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe

Gan & Lee Pharmaceuticals Receives European Commission Approval for Insulin Aspart Injection

BUZZ-China's Gan & Lee Pharmaceuticals heads for biggest drop in a year on lower Q1 results

BRIEF-Gan & Lee Pharmaceuticals 2025 Net Profit Up 86.1% Y/Y

Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1062 Injection

Gan & Lee Pharmaceuticals' Subsidiary Doses First Subject for Phase III of GZR33 Injection Trial; Shares Up 3%

BRIEF-Gan & Lee Pharmaceuticals - Signs Exclusive License Agreement With Jw Pharmaceutical

Gan & Lee Pharmaceuticals - Parties to Collaborate, Others on Clinical Development in South Korea of Bofanglutide Injection